2013
DOI: 10.1098/rsob.130002
|View full text |Cite
|
Sign up to set email alerts
|

Exploitation of bacterialN-linked glycosylation to develop a novel recombinant glycoconjugate vaccine againstFrancisella tularensis

Abstract: Glycoconjugate-based vaccines have proved to be effective at producing long-lasting protection against numerous pathogens. Here, we describe the application of bacterial protein glycan coupling technology (PGCT) to generate a novel recombinant glycoconjugate vaccine. We demonstrate the conjugation of the Francisella tularensis O-antigen to the Pseudomonas aeruginosa carrier protein exotoxin A using the Campylobacter jejuni PglB oligosaccharyltransferase. The resultant recombinant F. tularensis glycoconjugate v… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
101
0
3

Year Published

2014
2014
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 82 publications
(106 citation statements)
references
References 38 publications
2
101
0
3
Order By: Relevance
“…This strategy was only demonstrated in a few cases (Iwashkiw et al, 2012; Cuccui et al, 2013; Wetter et al, 2013). Since B. pseudomallei is a biosafety class III agent we were unable to directly exploit the native OPS II by expressing the N -glycosylation system in the host as previously shown (Iwashkiw et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…This strategy was only demonstrated in a few cases (Iwashkiw et al, 2012; Cuccui et al, 2013; Wetter et al, 2013). Since B. pseudomallei is a biosafety class III agent we were unable to directly exploit the native OPS II by expressing the N -glycosylation system in the host as previously shown (Iwashkiw et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…OTase-mediated N-glycosylation from Campylobacter jejuni has been successfully engineered in E. coli (33). Since then, numerous efforts have made to develop bioconjugate vaccines in E. coli against pathogens such as Francisella tularensis (34), Burkholderia pseudomallei (35), Shigella flexneri (36), and S. aureus (37) using this system. An OTase-mediated O-glycosylation system from Neisseria meningitides was established in Shigella spp.…”
Section: Discussionmentioning
confidence: 99%
“…This approach leverages laboratory strains of Escherichia coli for the expression of recombinant bacterial polysaccharides (e.g., O-polysaccharide antigens), which are conjugated in vivo to a co-expressed carrier protein by the Campylobacter jejuni oligosaccharyltransferase PglB. However, while PGCT has been used to make several novel protein/glycan combinations, it is limited by variable glycan conjugation efficiency as observed for certain heterologous polysaccharide substrates (Cuccui et al, 2013; Ihssen et al, 2015; Ihssen et al, 2010) and a challenging purification of the product antigen. This is particularly pertinent in the context of producing glycoconjugates carrying mammalian-like glycans (Cuccui and Wren, 2014).…”
Section: Introductionmentioning
confidence: 99%